The French group will need to answer questions about data and the rationale behind a full takeover to convince doubters.
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
Investors betting on the Principia short thesis face up to a clinical trial success that might not be what it seems.
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
Aurinia hopes to light up with Aurora data, while Principia's BTK inhibitor PRN1008 is put to the test.
Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
Promising mid-stage data with Merck KGaA’s evobrutinib in multiple sclerosis could help the German group carve out a niche for its BTK inhibitor – unless bigger players…